← Eichor
Study identifier: NCT05914987 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Determining Individualized Cancer Therapy in Pancreatic Cancer

Condition: Pancreatic Neoplasms  ·  Sponsor: Medical College of Wisconsin

PhaseN/A
Planned participants1000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a non-therapeutic exploratory observational precision oncology study designed to collect and analyze data that demonstrate the clinical efficacy and tolerability of personalized treatments based on molecular tumor profiling assessments (i.e., matched therapy) in adult pancreatic cancer patients. Patient medical records, obtained both retrospectively and prospectively, will be examined for results of molecular profiling obtained through standard of care testing to help understand how well molecular testing might predicts response to therapy. Patient demographic and outcome parameters to be evaluated include, but are not limited to, tumor response, time to treatment failure, patient survival, and toxicity.

This description comes directly from the study's public registry record.

Talk to the study team

Cancer Center Clinical Trials Office  ·  1-414-805-8900  ·  cccto@mcw.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Froedtert Hospital and the Medical College of WisconsinMilwaukee, Wisconsin, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05914987